Government of the Republic of Slovenia

Public bodySloveniagov.si

Its role Funder

project tracked
1
partner companies
2
news article
1

The Government of the Republic of Slovenia is the executive branch of the Slovenian state, responsible for the administration of government policies and the execution of laws passed by the National Assembly. It oversees a wide range of activities including economic development, industrial policy, and support for key sectors such as pharmaceuticals and biotechnology.

Read more

Headquartered in the capital city of Ljubljana, the government coordinates efforts across multiple ministries to promote investment and innovation within the country. In the context of the life sciences industry, it has provided state aid and investment incentives to attract major projects, including the construction of advanced production plants for biosimilar medicines.

The organization is structured as a public body with no private ownership, functioning as the highest level of executive power in Slovenia. It operates under the leadership of the Prime Minister and is accountable to the parliament and the public.

In the chemical and pharmaceutical industry, the Slovenian government acts as a facilitator for growth by offering financial support and regulatory guidance. This positions Slovenia as an attractive location for international companies seeking to establish manufacturing capabilities in Central Europe, contributing to job creation and technological advancement in the region.

The project Slovenian Government is involved in

chemXplore tracks 1 project involving Slovenian Government, of which one is active.

Sandoz biosimilar drug substance plant in Lendava, Slovenia
  1. Announced / Concept
  2. FEED / Pre-FID
  3. FID / Sanctioned
  4. Under Construction
  5. Commissioning & Start-up
Phase
Commissioning & Start-up
Where
Slovenia
Partners
Lek , Sandoz

Slovenian Government in chemical industry news

9 March 2023
Sandoz to Build New Biologics Plant in Slovenia

The $400M investment aims to boost biosimilar production, with operations starting in 2026. This supports the company's growth in biosimilars and antibiotics, enhancing access to critical medicines.

Where its projects are

active all projects